ECE2017 Eposter Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (145 abstracts)
Clinical and laboratorial reassessment of patients with isolated growth hormone deficiency during the transition phase
Ana Saavedra 1, , Juliana Oliveira 3 , Alexandra Martins 4 , Ana Azevedo 4 , Rita Santos-Silva 2, , Cíntia Castro 2, , Elisabete Rodrigues 1, , Davide Carvalho 1, & Manuel Fontoura 2,
1Department of Endocrinology, Diabetes and Metabolism of Centro Hospitalar de São João, Porto, Portugal; 2Faculty of Medicine, University of Porto, Porto, Portugal; 3Department of Pediatric Endocrinology, Hospital Pediátrico Integrado, Centro Hospitalar de São João, Porto, Portugal; 4Department of Pediatrics, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal.
Introduction: During childhood and puberty, growth hormone(GH) is essential for linear growth. Consequently, children with isolated GH deficiency(GHD) must receive replacement therapy. GH has also important metabolic actions. GHD in adults is associated with altered body composition. However, long-term consequences of GH treatment in adults is not sufficiently known.
Objective: To evaluate GH treatment during pediatric age in patients with isolated GHD.
Methods: Retrospective study of patients with isolated GHD followed in a tertiary hospital, which had undergone reassessment after finishing growth period. Anthropometric and analytical parameters before and after treatment were collected. SDS of anthropometric variables were calculated according WHO curves. IGF1 (Immulite 2000®) was analyzed considering SDS values adjusted for pubertal stage.
Results: Sample composed by 27 patients, 63% males. Before treatment: mean age was 10.5±3.7 years, mean height-SDS −2.82±0.77, IGF1-SDS levels −2.41±1.59 ng/ml with a mean difference of 2±1.5 years between chronological and bone age. All patients performed GH stimulation tests (clonidine, glucagon or insulin tolerance test) – peak values <7.0 μg/l. Three patients had abnormal pituitary MRI. Mean treatment duration was 5±3 years. Mean maximal dose administered was 0.03±0.01(mg/kg/day). No adverse effects were registered. At the end, final height-SDS was −1.63±0.64 and IGF1-SDS −0.83±2.34. Final height and target height differed in −4.72±6.07 cm. Nine patients kept follow-up in Endocrinology: 3 performed insulin tolerance test, all having normal results. Only 2 patients presented IGF-1 levels <-2 SDS (one of them proposed for treatment).
Discussion: As expected, patients with isolated GHD treated at our center showed good clinical outcomes, with mean final height reaching close target height. Current recommendations consider to treat with GH, adults with documented persistent deficiency. In this series all patients with isolated GHD with normal MRI had a transitory deficit and did not required treatment in the adult age.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more